

Ref: 90/SE/LC/2024-25

Date: 31/01/2025

To,  
**Head, Listing Compliance Department  
BSE Limited**  
Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

**Head, Listing Compliance Department  
National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051

**Scrip Code: 544122**

**Scrip Symbol: ENTERO**

Dear Sir/Madam,

**Subject: Intimation regarding receipt of listing and trading approval for 13,940 equity shares from the BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE')**

This is in continuation to our earlier communication dated January 16, 2025 regarding allotment of 13940 equity shares against exercise of stock options to the eligible employees of the Company under Entero Employee Stock Option Plan 2023 by the Board of Directors of the Company in its Meeting held on January 16, 2025.

We would like to inform that BSE vide letter reference no.: LOD / ESOP / TP / No. 13/ 2024-2025 dated January 31, 2025 and NSE vide letter reference no.: NSE/LIST/2025/46849 dated January 31, 2025 have given listing and trading approval. The above mentioned equity shares of the Company will be listed and admitted to dealings on the Exchanges w.e.f. February 01, 2025.

We would further like to inform you that the Issued, Paid-up, Admitted and Listed Equity Share Capital of the Company has been increased from Rs. 43,49,37,670 (consisting of 4,34,93,767 equity shares of face value of Rs. 10 each) to Rs. 43,50,77,070/- (consisting of 4,35,07,707 equity shares of face value of Rs. 10 each).

Copy of NSE and BSE approval letters are enclosed herewith.

This intimation is also made available on the Company's website.

This is for your information and records.

Yours Faithfully  
**For Entero Healthcare Solutions Limited**

Sanu Kapoor  
**Vice President-Legal, General Counsel, Company Secretary  
& Compliance Officer**

Encl. As above

**LOD / ESOP / TP / No. 13/ 2024-2025**

**" E - Letter "**

**Friday, January 31, 2025**

The Company Secretary  
Entero Healthcare Solutions Limited  
Plot No. I-35 Building - B Industrial Area Phase I  
13/7 Mathura Road  
121003

Dear Sir / Madam,

**Sub: Listing and Trading of 13940 Equity Shares of Rs. 10 bearing distinctive nos. 43493768 to 43507707 issued pursuant to ESOP.**

We acknowledge with thanks the receipt of your application and have pleasure in advising that effective from **Saturday, February 1, 2025** trading members of the Exchange are allowed to trade in your above-mentioned securities.

Please refer our Notice No. **20250131-14** dated **31/01/2025** available on our website issued in this behalf to the Trading Members of the Exchange, for your information, the contents of which may please be checked and confirmed to the Exchange.

Further, all critical price sensitive information and other submissions to be provided by the company pursuant to the SEBI(Listing Obligations and Disclosure Requirements), Regulations, 2015 may please be filed through listing centre. For details please refer to our notice no. 20151210 - 19 dated December 10, 2015 available on our website.

Yours faithfully,

**SD/-**  
**Rupal Khandelwal**  
**Deputy General Manager**  
Friday, January 31, 2025

**SD/-**  
**Prasad Bhide**  
**Senior Manager**

**National Stock Exchange Of India Limited**

Ref.: NSE/LIST/2025/46849

January 31, 2025

The Company Secretary  
Entero Healthcare Solutions Limited

Dear Sir/Madam,

**Sub: Listing of further issue under ESOP**

This is with reference to the application for the listing of further issue of 13940 Equity Shares of Rs. 10/- each allotted under ESOP made by the company. We are pleased to inform you that the above equity shares of the Company are listed and admitted to dealings on the Exchange from February 01, 2025 as per the details given below:

Sr. No.	Security Description	Symbol	Series	No. of securities	Distinctive Numbers
1.	Equity shares of Rs. 10/- each allotted under ESOP.	ENTERO	EQ	13940	43493768 to 43507707

Please note that all critical/price sensitive information and other submissions under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 shall be provided by the company through 'NEAPS' – NSE Electronic Application Processing System (<https://neaps.nseindia.com/NEWLISTINGCORP/>), an online filing facility provided by the Exchange, for quicker and efficient processing of your submissions.

If you require any further clarifications, we shall be glad to oblige.

Yours faithfully,  
For National Stock Exchange of India Limited

CC: National Securities Depository Limited  
4th Floor, Trade world,  
Kamala Mills Compound,  
Senapati Bapat Marg.,  
Lower Parel, Mumbai - 400 013

Central Depository Services Limited  
Marathon Futurex, A-Wing, 25th floor,  
N M Joshi Marg, Lower Parel,  
Mumbai – 400 013

P.S. Checklist of all the further issues is available on website of the exchange at the following URL:  
<https://www.nseindia.com/companies-listing/raising-capital-further-issues-main-sme-checklist>

*Note: This is a system generated document and hence is not required to be signed*